2014
Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development
Gu X, Chen N, Wei C, Liu S, Papadimitrakopoulou VA, Herbst RS, Lee JJ. Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development. Statistics In Biosciences 2014, 8: 99-128. PMID: 27617040, PMCID: PMC5014437, DOI: 10.1007/s12561-014-9124-2.Peer-Reviewed Original ResearchBiomarker profilesMD Anderson Cancer CenterPatient's biomarker profileChoice of treatmentAnderson Cancer CenterTreatment effectsMore effective treatmentsOverall treatment effectTargeted therapy developmentMore patientsCancer CenterLung cancerPredictive biomarkersPredictive markerAdaptive randomization designIndividual patientsEffective treatmentBetter outcomesTreatment efficacyPatientsBayesian adaptive designRelevant biomarkersKnown markerTherapy developmentBest treatment
2008
Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine
Xian Zhou, Suyu Liu, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine. Clinical Trials 2008, 5: 181-193. PMID: 18559407, PMCID: PMC5481999, DOI: 10.1177/1740774508091815.Peer-Reviewed Original ResearchConceptsDisease control rateBiomarker profilesControl rateTrial designRandomization ratesEffective agentLung cancerAdvanced stage non-small cell lung cancerStage non-small cell lung cancerNon-small cell lung cancerBaseline biopsy samplesPatient's biomarker profileCell lung cancerEarly stopping ruleEvaluable patientsPrimary endpointMore patientsPersonalized medicineAdaptive randomization designEffective treatmentBiomarker assessmentBiopsy samplesPatientsBayesian adaptive designIndividual tumors